Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients.

Barbieri C, Bolzoni E, Mari F, Cattinelli I, Bellocchio F, Martin JD, Amato C, Stopper A, Gatti E, Macdougall IC, Stuard S, Canaud B.

PLoS One. 2016 Mar 3;11(3):e0148938. doi: 10.1371/journal.pone.0148938. eCollection 2016.

2.

Trends in Anemia Management in Hemodialysis Patients with Cancer.

Butler AM, Kshirsagar AV, Olshan AF, Nielsen ME, Wheeler SB, Brookhart MA.

Am J Nephrol. 2015;42(3):206-15. doi: 10.1159/000440771. Epub 2015 Oct 7.

3.

Secondary haemochromatosis in a haemodialysis patient.

Cheng L, Tang X, Fu P, Liu F.

Singapore Med J. 2015 Jul;56(7):e124-6. doi: 10.11622/smedj.2015116.

4.

"Out of Sight, Out of Mind": The Failed Renal Allograft as a Cause of ESA Resistance.

Mehrotra A, Tan JA, Ames SA.

Semin Dial. 2015 Sep-Oct;28(5):530-2. doi: 10.1111/sdi.12401. Epub 2015 Jun 21.

5.

Anemia in patients on chronic hemodialysis in Cameroon: prevalence, characteristics and management in low resources setting.

Kaze FF, Kengne AP, Mambap AT, Halle MP, Mbanya D, Ashuntantang G.

Afr Health Sci. 2015 Mar;15(1):253-60. doi: 10.4314/ahs.v15i1.33.

6.

Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010).

Winkelmayer WC, Mitani AA, Goldstein BA, Brookhart MA, Chertow GM.

JAMA Intern Med. 2014 May;174(5):699-707.

7.

Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long-term hemodialysis.

Oh J, Joo KW, Chin HJ, Chae DW, Kim SG, Kim SJ, Chung W, Kim S, Huh W, Oh HY, Choi BS, Yang CW, Kim S.

J Korean Med Sci. 2014 Jan;29(1):76-83. doi: 10.3346/jkms.2014.29.1.76. Epub 2013 Dec 26.

8.

Dose conversion ratio in hemodialysis patients switched from darbepoetin alfa to PEG-epoetin beta: AFFIRM study.

Choi P, Farouk M, Manamley N, Addison J.

Adv Ther. 2013 Nov;30(11):1007-17. doi: 10.1007/s12325-013-0063-y. Epub 2013 Oct 31.

9.

Red blood cell transfusion risks in patients with end-stage renal disease.

Tanhehco YC, Berns JS.

Semin Dial. 2012 Sep-Oct;25(5):539-44. doi: 10.1111/j.1525-139X.2012.01089.x. Epub 2012 Jun 11. Review.

10.

Associations of pre-transplant anemia management with post-transplant delayed graft function in kidney transplant recipients.

Molnar MZ, Kovesdy CP, Rosivall L, Bunnapradist S, Hoshino J, Streja E, Krishnan M, Kalantar-Zadeh K.

Clin Transplant. 2012 Sep-Oct;26(5):782-91. doi: 10.1111/j.1399-0012.2012.01598.x. Epub 2012 Mar 12.

11.

Efficacy of HBV vaccination in various stages of chronic kidney disease: is earlier better?

Hashemi B, Mahdavi-Mazdeh M, Abbasi M, Hosseini-Moghaddam SM, Zinat NH, Ahmadi F.

Hepat Mon. 2011 Oct;11(10):816-20. doi: 10.5812/kowsar.1735143X.751.

12.

A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia.

Pergola PE, Gartenberg G, Fu M, Wolfson M, Rao S, Bowers P.

Clin J Am Soc Nephrol. 2009 Nov;4(11):1731-40. doi: 10.2215/CJN.03470509. Epub 2009 Sep 17.

13.

Coronary artery bypass grafting in a dialysis-dependent Jehovah's Witness.

Williams M, Blocksom JM, Baciewicz FA Jr.

Tex Heart Inst J. 2004;31(2):181-3; discussion 183.

14.

Recombinant erythropoietin in clinical practice.

Ng T, Marx G, Littlewood T, Macdougall I.

Postgrad Med J. 2003 Jul;79(933):367-76. Review.

16.
17.

Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease.

Stevens ME, Summerfield GP, Hall AA, Beck CA, Harding AJ, Cove-Smith JR, Paterson AD.

BMJ. 1992 Feb 22;304(6825):474-7.

18.

The use of erythropoietin in renal failure.

Macdougall IC, Hutton RD, Coles GA, Williams JD.

Postgrad Med J. 1991 Jan;67(783):9-15. Review.

Supplemental Content

Loading ...
Support Center